Urogen Pharma Ltd
URGN3.997USD
-0.173-4.16%
交易中 （美东）报价延迟15分钟
168.78M总市值
亏损市盈率 TTM
关于 Urogen Pharma Ltd 公司
UroGen Pharma Ltd. 是一家位于以色列的生物制药公司。该公司致力于为癌症和泌尿系统疾病提供解决方案。UroGen 开发了 RTGelTM 逆向热凝胶，这是一种专有的缓释水凝胶平台技术，有可能改善现有药物的治疗效果。其主要候选产品包括 MitoGel 和 VesiGel，采用其专有的逆向热触发水凝胶或 RTGel 技术配制而成。MiroGel (UGN-101) 是化疗药物丝裂霉素 C 的缓释制剂，用于治疗低级别上尿路上皮癌，这是一种上尿路上皮癌。VesiGel (UGN-102) 是高剂量丝裂霉素 C 的缓释制剂，用于治疗低级别非肌层浸润性膀胱癌 (LG-NMIBC)。
公司简介
公司代码URGN
公司名称Urogen Pharma Ltd
上市日期May 04, 2017
成立日期2004
CEOMs. Elizabeth A. (Liz) Barrett
员工数量235
证券类型Ordinary Share
年结日May 04
公司地址9 Ha'ta'asiya St
城市RA'ANANA
上市交易所NASDAQ Global Market Consolidated
国家Israel
邮编4365007
电话97297707601
网址https://www.urogen.com/
公司代码URGN
上市日期May 04, 2017
成立日期2004
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.94K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
32.51K
+28.89%
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Christopher Degnan
Mr. Christopher Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.94K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
32.51K
+28.89%
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
Jelmyto
90.40M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
Jelmyto
90.40M
0.00%
股东统计
更新时间: 15 小时前
更新时间: 15 小时前
持股股东
股东类型
持股股东
股东统计
占比
RTW Investments L.P.
8.32%
RA Capital Management, LP
6.95%
UBS Asset Management (Switzerland)
5.73%
Menora Mivtachim Insurance Ltd.
4.99%
Vestal Point Capital, LP
4.67%
Other
69.34%
持股股东
股东统计
占比
RTW Investments L.P.
8.32%
RA Capital Management, LP
6.95%
UBS Asset Management (Switzerland)
5.73%
Menora Mivtachim Insurance Ltd.
4.99%
Vestal Point Capital, LP
4.67%
Other
69.34%
股东类型
股东统计
占比
Investment Advisor
27.55%
Investment Advisor/Hedge Fund
24.49%
Hedge Fund
23.99%
Research Firm
8.75%
Insurance Company
6.73%
Venture Capital
3.28%
Corporation
2.97%
Bank and Trust
2.55%
Individual Investor
2.05%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
278
43.89M
96.97%
-2.00M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
2023Q1
221
19.00M
81.20%
-1.17M
2022Q4
218
18.34M
79.80%
-1.99M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
3.83M
8.32%
+47.45K
+1.25%
Dec 31, 2024
UBS Asset Management (Switzerland)
1.36M
2.94%
+1.36M
--
Dec 31, 2024
Menora Mivtachim Insurance Ltd.
2.30M
5%
--
--
Mar 11, 2025
Vestal Point Capital, LP
1.63M
3.54%
+1.23M
+307.50%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
2.19M
4.76%
-23.39K
-1.06%
Dec 31, 2024
TD Securities, Inc.
1.75M
3.79%
+1.75M
--
Dec 31, 2024
Acorn Capital Advisors, LLC
1.52M
3.29%
+1.52M
--
Dec 31, 2024
Pontifax Venture Capital
1.49M
3.22%
-1.00
-0.00%
Mar 14, 2024
查看更多
持股ETF
更新时间: 5月6日 周二
更新时间: 5月6日 周二
机构名称
占比
ARK Israel Innovative Technology ETF
2.02%
ALPS Medical Breakthroughs ETF
0.38%
Amplify BlueStar Israel Technology ETF
0.36%
iShares Micro-Cap ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
查看更多
ARK Israel Innovative Technology ETF
占比2.02%
ALPS Medical Breakthroughs ETF
占比0.38%
Amplify BlueStar Israel Technology ETF
占比0.36%
iShares Micro-Cap ETF
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.05%
iShares Biotechnology ETF
占比0.04%
SPDR S&P International Small Cap ETF
占比0.03%
iShares Russell 2000 Growth ETF
占比0.02%
Global X Russell 2000 ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
